WAVE Life Sciences
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
733 Concord Ave, Cambridge, Massachusett...Phone Number
(617) 949-2900Website
www.wavelifesciences.comRevenue
$71.8 MillionStock Symbol
WVEIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About WAVE Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.Explore more
WAVE Life Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is WAVE Life Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at WAVE Life Sciences
Funding: Get notified immidiatlly once WAVE Life Sciences has new funding data
Click to see if WAVE Life Sciences had a recent Job posting/layoffs
Check if WAVE Life Sciences has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on WAVE Life Sciences recently announced quarterly report
Product Launch: Get notified when WAVE Life Sciences launches new products
WAVE Life Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if WAVE Life Sciences is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to WAVE Life Sciences
Compare insights from companies similar to WAVE Life Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
WAVE Life Sciences
$71.8M
201-500
Public
$451.3M
2012
LR
Linda RockettSenior Vice President, General Counsel
Company Profile Activity
Activity Insights
WAVE Life Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
WAVE Life Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about WAVE Life Sciences.
WAVE Life Sciences financials insights
Gather financial insights about WAVE Life Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Multiple Rounds
$196M
2017
Stock Offering
$93.5M
2019
Stock Offering
$161.8M
WAVE Life Sciences Tech Stack
A closer look at the technologies used by WAVE Life Sciences
See more technologies
Most Recent Scoops
Open Position
Project
WAVE Life Sciences has announced that it expects regulatory feedback this summer on next steps toward accelerated approval for its AATD program, with the established regulatory benchmark set at total AAT levels greater than 11 micromolar.
Pharmaceuticals
Project
WAVE Life Sciences has announced plans to initiate a combination study evaluating its INHBE program alongside incretins, including tirzepatide at starting doses such as 5 mg, with the goal of maximizing fat loss and lean mass preservation while improving tolerability and adherence without escalating incretin doses.
Medical Research, Pharmaceuticals
Project
WAVE Life Sciences has reported key biomarker data from its AATD program, including a substantial reduction in Z protein, 64% M wild-type protein in circulation in the MZ patient population, total AAT levels meeting or exceeding the MZ phenotype threshold, and a dynamic acute phase response producing over 20 micromolar of protein during acute phase events sustained for months before returning to baseline.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
WAVE Life Sciences News & Media
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company’s second quarter 2026 financial results and provide business updates.Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approval required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrangWave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosingIs Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?
Is WVE a good stock to buy? We came across a bullish thesis on Wave Life Sciences Ltd. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on WVE. Wave Life Sciences Ltd.’s share was trading at $5.70 as of June 8th. Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding WAVE Life Sciences
Sign Up For FreeTo access detailed company insights
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables t... Read More
